Article
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
All News
Article
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Article
Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Article
A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.
Article
A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.
Article
Denosumab is effective in osteoporosis when used on schedue, but research suggests that discontinuation leads to rapid reversal of effect; a new observational study has shown that delays in denosumab administration of more than 16 weeks results in an increased vertebral fracture risk, according t
Dr. John Cush
Tweet
Another case of COVID-19 Arthritis; 58 yoF w/ non-severe COVID-19, (by qRT-PCR ) had arthralgia, fever, cough, nausea, diarrhoea, dysgeusia, and devloped ankle arthritis CRP 7·36 mg/L, lymphopenia (1·29) persistent arthritis (by US) and +Sars-CoV-2 in SF. https://t.co/4Pg1Vq30EN
Victoria Shanmugam
Tweet
#WomenInMedicine now that we have data from @NEJM - how do we help institutions work with women to address these challenges together? https://t.co/kEyegOCfE3
Mike Putman
Tweet
Excellent review of IgG4-RD, @NatRevRheumatol
IgG4-RD is indolent (afebrile, etc) but 60% of pts have irreversible damage at dx!
Universal response to GC but 40% not in remission at 1yr; B-cell tx can bring about "dramatic response"
Good read & topic: https://t.co/Mbrq7bFHk0 https://t.co/8oQF08qzit
Dr. John Cush
Tweet
Study of 193 Axial SpA pts with TNF inhibitor switching shows, using stringent outcome measures (ASDAS-ID) shows odds of responding to 2nd TNFi best w/ secondary TNFi failure (OR 7.3) or adverse events (OR 9.1), compared to primary TNFi failure. https://t.co/kpDelzBYRe
Dr. John Cush
Tweet
Study of 222 RA pts on MTX given anti-GMCSF (otilimab) 22·5 mg, 45 mg, 90 mg, 135 mg, 180 mg, or PBO weekly x 5 wks, then EOW. @wk 24 DAS28-CRP <2·6 5%, 16%. 19%, 14%, 14% respectively and 3% in PBO. Otilimab failed to meet primary endpoint. https://t.co/14QqyeTcuP
Dr. John Cush
Tweet
Comparison of 34,128 COVID and 84,585 influenza pts; COVID-19 patients have been more typically been male, younger, and have fewer comorbidities and lower medication use than flu. (data from USA, South Korea, Spain) https://t.co/VUzVxFdBra
Dr. John Cush
Tweet
Lockdown worsening; UK survey 678 patients musculoskeletal diseases pts in late April 2020 shows 53% worsening of Sx; 1/3 had clinic/hosp access probs problems & most (88%) had no probs w/ getting meds; but 44% needed others to help them get meds. https://t.co/3efmTdHhQx
Dr. John Cush
Tweet
Among 4766 mental health pts admited for Psychosis; 19% ANA tested and only 135 had a positive ANA >=1:160. (15% of those tested). Only 4 met 2019 ACR/EULAR criteria for SLE, and 2/4 met criteria for NPSLE. NPSLE prevalence was 1.5% in ANA+ psychosis Pts. https://t.co/c5C1VQaQAI
NM Rheumatology
Tweet
How pregnancy impacts nr-axSpA disease activity can vary from one woman to another, according to Eric Ruderman, MD, “I’ve had some patients who are better during pregnancy, and some who aren’t,” says Dr. Ruderman. Learn more about pregnancy and nr-axSpA:
https://t.co/mC6YcG5lIx
NYT Health
Tweet
To quash the virus, the immune system unleashes an arsenal. Sometimes these weapons turn inward and destroy healthy tissues. Combatting this friendly fire has become as crucial a part of the Covid-19 treatment strategy as subduing the virus itself. https://t.co/FrxVfSleEH
WOMEN IN RHEUM
Tweet
The AWIR San Diego, CA Virtual Summit
CME Accredited : Worth 3.0 CEU Credits™
October 11th | Register Now:
https://t.co/4vSqD0bxpk
Join us on October 11th as we discuss Spondyloarthritis & the Spine, Telehealth regulatory updates, and more! For MD, NP, PA & PharmD Health Prof. https://t.co/QLXVJYjTD2
Dr. Dinesh Khanna
Tweet
Dr. Dinesh Khanna
Tweet
1) If you are have diffuse scleroderma and have previously participated in a clinical trial, we need your help! You will be asked to watch video tutorial and answer a survey which will take you 20 minutes to complete. the study is supported by @WeAreSRUK @scleroderma @srfcure
Jeff Sparks
Tweet
Incredible lecture on the highest of therapeutics for rheumatoid arthritis by @BrighamWomens Dr Michael Weinblatt. Love this screen shot of A to Z for therapies prior to the methotrexate era. Z=Zero therapy (do nothing). Incredible advances since then! https://t.co/AOIMBJiulo
